Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms
In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside supplementation increased blood NAD levels but failed to improve clinical outcomes…